The International Dialogue on the Evaluation of Allergens (IDEA) is a multi-stakeholder initiative conceived with the backing and oversight of the European Commission and their scientific advisors.
The IDEA Project's 2024 surveillance initiative focuses on collecting clinical data on fragrance allergies to assess the effectiveness of preventive measures. Launched in response to concerns from the SCCS, this effort collaborates with 10 clinics across eight European countries, ensuring high-quality patch test readings. Testing began in November 2024, with initial patient data expected by year-end. In 2025, the first testing round will be completed, with outcomes analyzed to refine methodologies and enhance the study's reliability.
Find out more about the IDEA project by visiting: https://ideaproject.info/
In 2024, the IDEA project focused on incorporating New Approach Methodologies (NAMs) into refining the Quantitative Risk Assessment (QRA) for fragrance allergens. Key progress included extending the Reference Chemical Potency List (RCPL) and evaluating its use for skin sensitization potency. In 2025, IDEA will continue expanding the RCPL and applying it to NAMs, with plans for a stakeholder workshop and regulatory review. The project aims to enhance allergen safety globally and secure QRA endorsement in Europe and worldwide.
Find out more about the IDEA project by visiting: https://ideaproject.info/